Table 1.

Patient and disease characteristics

AKT1-mutant, n = 153, N (%)AKT1–wild-type, n = 302, N (%)All, n = 455, N (%)
Age at diagnosis, median (range), years50 (28–74)50 (25–83)50 (25–83)
Race
 White124 (81%)227 (75%)351 (77%)
 Black9 (6%)18 (6%)27 (6%)
 Other/unknown20 (13%)57 (19%)77 (17%)
Stage at primary diagnosis
 00 (0%)5 (2%)5 (1%)
 123 (15%)51 (17%)74 (16%)
 252 (34%)82 (27%)134 (30%)
 337 (24%)70 (23%)107 (24%)
 426 (17%)77 (26%)103 (23%)
 Unknown15 (10%)17 (6%)32 (7%)
Histologic subtype
 Ductal106 (69%)218 (72%)324 (71%)
 Lobular28 (18%)52 (17%)80 (18%)
 Other19 (12%)32 (11%)51 (11%)
Overall tumor grade
 17 (5%)20 (7%)27 (6%)
 266 (43%)118 (39%)184 (40%)
 343 (28%)121 (40%)164 (36%)
Unknown37 (24%)43 (14%)80 (18%)
HER2 status
 Negative140 (92%)273 (90%)413 (91%)
 Positive3 (2%)6 (2%)9 (2%)
 Unknown10 (7%)23 (8%)33 (7%)
Locoregional recurrencea26 (21%)48 (21%)74 (21%)
  • Abbreviation: HER2, human epidermal growth factor receptor 2.

  • aAmong the 352 non–stage 4 patients.